VXRT Vaxart, Inc.
Vaxart, Inc. (VXRT) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.8% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vaxart, Inc.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.